NEW YORK, May 15, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the Board of Directors of
Intermolecular, Inc. ("Intermolecular" or the "Company") (NASDAQ:
IMI) in connection with the proposed acquisition of the Company by
a wholly owned subsidiary of Merck KGaA. Under the terms of
the acquisition agreement valued at $62
million, shareholders will receive $1.20 per share in cash.
If you own IMI shares and wish to discuss this
investigation or have any questions concerning this notice or your
rights or interests, please contact:
Joshua
Rubin
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Visit our
website
http://www.weisslawllp.com/
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether Intermolecular's Board acted
to maximize shareholder value prior to entering into the
agreement.
WeissLaw is concentrating its investigation on whether
Intermolecular's Board conducted a fair process in agreeing to the
proposed acquisition, and whether the proposed acquisition
undervalues the Company.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-intermolecular-inc-acquisition-300851308.html
SOURCE WeissLaw LLP